CGS-authored
The proposal had been scheduled to be taken up tomorrow by the governing board of the $3 billion agency, but the board's standards working group delayed action.
In response to a question, Kevin McCormack, a spokesman for the agency, said in an email,
“It was felt that more discussion was needed before moving to a vote so another meeting is going to be scheduled.”
In 2006, the CIRM governing board approved regulations that banned the use of CIRM funds for stem cells lines derived using compensation. That rule would be modified under today's plan, which would permit the CIRM governing board to approve the use of such lines following a staff study evaluating scientific and ethical issues. Their use would be allowed if the lines would “advance CIRM's mission.”
The delay came after four organizations, including the Center for Genetics and Society in Berkeley, argued that the plan...